Elzonris is a medicine used to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a type of blood cancer which can affect many organs including the skin, the bone marrow (the spongy tissue inside the large bones) and the lymph nodes. BPDCN is rare, and Elzonris was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 11 November 2015.
Therapeutic Indication
### Therapeutic indication Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Therapeutic Area (MeSH)
ATC Code
L01XX67
ATC Item
tagraxofusp
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| tagraxofusp | N/A | Tagraxofusp |
EMA Name
Elzonris
Medicine Name
Elzonris
Aliases
N/ANo risk management plan link.
